The global market for Gastroesophageal Reflux Disease Therapeutics was estimated to be worth US$ 4801.8 million in 2023 and is forecast to a readjusted size of US$ 4286.6 million by 2030 with a CAGR of -1.6% during the forecast period 2024-2030

Gastroesophageal Reflux Disease Therapeutics - Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Gastroesophageal Reflux Disease Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Gastroesophageal Reflux Disease Therapeutics by region & country, by Type, and by Application.

The Gastroesophageal Reflux Disease Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastroesophageal Reflux Disease Therapeutics.

Market Segmentation

Scope of Gastroesophageal Reflux Disease Therapeutics - Market Report

Report Metric	Details
Report Name	Gastroesophageal Reflux Disease Therapeutics - Market
Forecasted market size in 2030	US$ 4286.6 million
Forecasted years	2024 - 2030
Segment by Type:	Antacids H2 Receptor Blockers Proton Pump Inhibitors (PPIs) Pro-kinetic Agents Others
Segment by Application	Hospital Pharmacy Drug Stores General Stores Supermarkets
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AstraZeneca, Eisai, Takeda Pharmaceutical, GlaxoSmithKline, Johnson & Johnson, Daewoong Pharmaceutical, Ironwood Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Gastroesophageal Reflux Disease Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Gastroesophageal Reflux Disease Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Gastroesophageal Reflux Disease Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Gastroesophageal Reflux Disease Therapeutics - Market size in 2030?

Ans: The Gastroesophageal Reflux Disease Therapeutics - Market size in 2030 will be US$ 4286.6 million.

Who are the main players in the Gastroesophageal Reflux Disease Therapeutics - Market report?

Ans: The main players in the Gastroesophageal Reflux Disease Therapeutics - Market are AstraZeneca, Eisai, Takeda Pharmaceutical, GlaxoSmithKline, Johnson & Johnson, Daewoong Pharmaceutical, Ironwood Pharmaceuticals

What are the Application segmentation covered in the Gastroesophageal Reflux Disease Therapeutics - Market report?

Ans: The Applications covered in the Gastroesophageal Reflux Disease Therapeutics - Market report are Hospital Pharmacy, Drug Stores, General Stores, Supermarkets

What are the Type segmentation covered in the Gastroesophageal Reflux Disease Therapeutics - Market report?

Ans: The Types covered in the Gastroesophageal Reflux Disease Therapeutics - Market report are Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), Pro-kinetic Agents, Others

1 Market Overview

1.1 Gastroesophageal Reflux Disease Therapeutics Product Introduction

1.2 Global Gastroesophageal Reflux Disease Therapeutics Market Size Forecast

1.3 Gastroesophageal Reflux Disease Therapeutics Market Trends & Drivers

1.3.1 Gastroesophageal Reflux Disease Therapeutics Industry Trends

1.3.2 Gastroesophageal Reflux Disease Therapeutics Market Drivers & Opportunity

1.3.3 Gastroesophageal Reflux Disease Therapeutics Market Challenges

1.3.4 Gastroesophageal Reflux Disease Therapeutics Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Gastroesophageal Reflux Disease Therapeutics Players Revenue Ranking (2023)

2.2 Global Gastroesophageal Reflux Disease Therapeutics Revenue by Company (2019-2024)

2.3 Key Companies Gastroesophageal Reflux Disease Therapeutics Manufacturing Base Distribution and Headquarters

2.4 Key Companies Gastroesophageal Reflux Disease Therapeutics Product Offered

2.5 Key Companies Time to Begin Mass Production of Gastroesophageal Reflux Disease Therapeutics

2.6 Gastroesophageal Reflux Disease Therapeutics Market Competitive Analysis

2.6.1 Gastroesophageal Reflux Disease Therapeutics Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Gastroesophageal Reflux Disease Therapeutics Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastroesophageal Reflux Disease Therapeutics as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Antacids

3.1.2 H2 Receptor Blockers

3.1.3 Proton Pump Inhibitors (PPIs)

3.1.4 Pro-kinetic Agents

3.1.5 Others

3.2 Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Type

3.2.1 Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Gastroesophageal Reflux Disease Therapeutics Sales Value, by Type (2019-2030)

3.2.3 Global Gastroesophageal Reflux Disease Therapeutics Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital Pharmacy

4.1.2 Drug Stores

4.1.3 General Stores

4.1.4 Supermarkets

4.2 Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Application

4.2.1 Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Gastroesophageal Reflux Disease Therapeutics Sales Value, by Application (2019-2030)

4.2.3 Global Gastroesophageal Reflux Disease Therapeutics Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Region

5.1.1 Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Region (2019-2024)

5.1.3 Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Region (2025-2030)

5.1.4 Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Gastroesophageal Reflux Disease Therapeutics Sales Value, 2019-2030

5.2.2 North America Gastroesophageal Reflux Disease Therapeutics Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Gastroesophageal Reflux Disease Therapeutics Sales Value, 2019-2030

5.3.2 Europe Gastroesophageal Reflux Disease Therapeutics Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Sales Value, 2019-2030

5.4.2 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Gastroesophageal Reflux Disease Therapeutics Sales Value, 2019-2030

5.5.2 South America Gastroesophageal Reflux Disease Therapeutics Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Gastroesophageal Reflux Disease Therapeutics Sales Value, 2019-2030

5.6.2 Middle East & Africa Gastroesophageal Reflux Disease Therapeutics Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Gastroesophageal Reflux Disease Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Gastroesophageal Reflux Disease Therapeutics Sales Value

6.3 United States

6.3.1 United States Gastroesophageal Reflux Disease Therapeutics Sales Value, 2019-2030

6.3.2 United States Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Gastroesophageal Reflux Disease Therapeutics Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Gastroesophageal Reflux Disease Therapeutics Sales Value, 2019-2030

6.4.2 Europe Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Gastroesophageal Reflux Disease Therapeutics Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Gastroesophageal Reflux Disease Therapeutics Sales Value, 2019-2030

6.5.2 China Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (%), 2023 VS 2030

6.5.3 China Gastroesophageal Reflux Disease Therapeutics Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Gastroesophageal Reflux Disease Therapeutics Sales Value, 2019-2030

6.6.2 Japan Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Gastroesophageal Reflux Disease Therapeutics Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Gastroesophageal Reflux Disease Therapeutics Sales Value, 2019-2030

6.7.2 South Korea Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Gastroesophageal Reflux Disease Therapeutics Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Gastroesophageal Reflux Disease Therapeutics Sales Value, 2019-2030

6.8.2 Southeast Asia Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Gastroesophageal Reflux Disease Therapeutics Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Gastroesophageal Reflux Disease Therapeutics Sales Value, 2019-2030

6.9.2 India Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (%), 2023 VS 2030

6.9.3 India Gastroesophageal Reflux Disease Therapeutics Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 AstraZeneca

7.1.1 AstraZeneca Profile

7.1.2 AstraZeneca Main Business

7.1.3 AstraZeneca Gastroesophageal Reflux Disease Therapeutics Products, Services and Solutions

7.1.4 AstraZeneca Gastroesophageal Reflux Disease Therapeutics Revenue (US$ Million) & (2019-2024)

7.1.5 AstraZeneca Recent Developments

7.2 Eisai

7.2.1 Eisai Profile

7.2.2 Eisai Main Business

7.2.3 Eisai Gastroesophageal Reflux Disease Therapeutics Products, Services and Solutions

7.2.4 Eisai Gastroesophageal Reflux Disease Therapeutics Revenue (US$ Million) & (2019-2024)

7.2.5 Eisai Recent Developments

7.3 Takeda Pharmaceutical

7.3.1 Takeda Pharmaceutical Profile

7.3.2 Takeda Pharmaceutical Main Business

7.3.3 Takeda Pharmaceutical Gastroesophageal Reflux Disease Therapeutics Products, Services and Solutions

7.3.4 Takeda Pharmaceutical Gastroesophageal Reflux Disease Therapeutics Revenue (US$ Million) & (2019-2024)

7.3.5 GlaxoSmithKline Recent Developments

7.4 GlaxoSmithKline

7.4.1 GlaxoSmithKline Profile

7.4.2 GlaxoSmithKline Main Business

7.4.3 GlaxoSmithKline Gastroesophageal Reflux Disease Therapeutics Products, Services and Solutions

7.4.4 GlaxoSmithKline Gastroesophageal Reflux Disease Therapeutics Revenue (US$ Million) & (2019-2024)

7.4.5 GlaxoSmithKline Recent Developments

7.5 Johnson & Johnson

7.5.1 Johnson & Johnson Profile

7.5.2 Johnson & Johnson Main Business

7.5.3 Johnson & Johnson Gastroesophageal Reflux Disease Therapeutics Products, Services and Solutions

7.5.4 Johnson & Johnson Gastroesophageal Reflux Disease Therapeutics Revenue (US$ Million) & (2019-2024)

7.5.5 Johnson & Johnson Recent Developments

7.6 Daewoong Pharmaceutical

7.6.1 Daewoong Pharmaceutical Profile

7.6.2 Daewoong Pharmaceutical Main Business

7.6.3 Daewoong Pharmaceutical Gastroesophageal Reflux Disease Therapeutics Products, Services and Solutions

7.6.4 Daewoong Pharmaceutical Gastroesophageal Reflux Disease Therapeutics Revenue (US$ Million) & (2019-2024)

7.6.5 Daewoong Pharmaceutical Recent Developments

7.7 Ironwood Pharmaceuticals

7.7.1 Ironwood Pharmaceuticals Profile

7.7.2 Ironwood Pharmaceuticals Main Business

7.7.3 Ironwood Pharmaceuticals Gastroesophageal Reflux Disease Therapeutics Products, Services and Solutions

7.7.4 Ironwood Pharmaceuticals Gastroesophageal Reflux Disease Therapeutics Revenue (US$ Million) & (2019-2024)

7.7.5 Ironwood Pharmaceuticals Recent Developments

8 Industry Chain Analysis

8.1 Gastroesophageal Reflux Disease Therapeutics Industrial Chain

8.2 Gastroesophageal Reflux Disease Therapeutics Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Gastroesophageal Reflux Disease Therapeutics Sales Model

8.5.2 Sales Channel

8.5.3 Gastroesophageal Reflux Disease Therapeutics Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Astrazeneca plc

Eisai Co Ltd

Takeda Pharmaceutical

GlaxoSmithKline PLC

Johnson & Johnson

Daewoong Pharmaceutical

Ironwood Pharmaceuticals

List of Tables

Table 1. Gastroesophageal Reflux Disease Therapeutics Market Trends

Table 2. Gastroesophageal Reflux Disease Therapeutics Market Drivers & Opportunity

Table 3. Gastroesophageal Reflux Disease Therapeutics Market Challenges

Table 4. Gastroesophageal Reflux Disease Therapeutics Market Restraints

Table 5. Global Gastroesophageal Reflux Disease Therapeutics Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Gastroesophageal Reflux Disease Therapeutics Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Gastroesophageal Reflux Disease Therapeutics Product Type

Table 9. Key Companies Time to Begin Mass Production of Gastroesophageal Reflux Disease Therapeutics

Table 10. Global Gastroesophageal Reflux Disease Therapeutics Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastroesophageal Reflux Disease Therapeutics as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Gastroesophageal Reflux Disease Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Gastroesophageal Reflux Disease Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Gastroesophageal Reflux Disease Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Gastroesophageal Reflux Disease Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Region (2019-2024) & (%)

Table 27. Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Gastroesophageal Reflux Disease Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Gastroesophageal Reflux Disease Therapeutics Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Gastroesophageal Reflux Disease Therapeutics Sales Value, (2025-2030) & (US$ Million)

Table 31. AstraZeneca Basic Information List

Table 32. AstraZeneca Description and Business Overview

Table 33. AstraZeneca Gastroesophageal Reflux Disease Therapeutics Products, Services and Solutions

Table 34. Revenue (US$ Million) in Gastroesophageal Reflux Disease Therapeutics Business of AstraZeneca (2019-2024)

Table 35. AstraZeneca Recent Developments

Table 36. Eisai Basic Information List

Table 37. Eisai Description and Business Overview

Table 38. Eisai Gastroesophageal Reflux Disease Therapeutics Products, Services and Solutions

Table 39. Revenue (US$ Million) in Gastroesophageal Reflux Disease Therapeutics Business of Eisai (2019-2024)

Table 40. Eisai Recent Developments

Table 41. Takeda Pharmaceutical Basic Information List

Table 42. Takeda Pharmaceutical Description and Business Overview

Table 43. Takeda Pharmaceutical Gastroesophageal Reflux Disease Therapeutics Products, Services and Solutions

Table 44. Revenue (US$ Million) in Gastroesophageal Reflux Disease Therapeutics Business of Takeda Pharmaceutical (2019-2024)

Table 45. Takeda Pharmaceutical Recent Developments

Table 46. GlaxoSmithKline Basic Information List

Table 47. GlaxoSmithKline Description and Business Overview

Table 48. GlaxoSmithKline Gastroesophageal Reflux Disease Therapeutics Products, Services and Solutions

Table 49. Revenue (US$ Million) in Gastroesophageal Reflux Disease Therapeutics Business of GlaxoSmithKline (2019-2024)

Table 50. GlaxoSmithKline Recent Developments

Table 51. Johnson & Johnson Basic Information List

Table 52. Johnson & Johnson Description and Business Overview

Table 53. Johnson & Johnson Gastroesophageal Reflux Disease Therapeutics Products, Services and Solutions

Table 54. Revenue (US$ Million) in Gastroesophageal Reflux Disease Therapeutics Business of Johnson & Johnson (2019-2024)

Table 55. Johnson & Johnson Recent Developments

Table 56. Daewoong Pharmaceutical Basic Information List

Table 57. Daewoong Pharmaceutical Description and Business Overview

Table 58. Daewoong Pharmaceutical Gastroesophageal Reflux Disease Therapeutics Products, Services and Solutions

Table 59. Revenue (US$ Million) in Gastroesophageal Reflux Disease Therapeutics Business of Daewoong Pharmaceutical (2019-2024)

Table 60. Daewoong Pharmaceutical Recent Developments

Table 61. Ironwood Pharmaceuticals Basic Information List

Table 62. Ironwood Pharmaceuticals Description and Business Overview

Table 63. Ironwood Pharmaceuticals Gastroesophageal Reflux Disease Therapeutics Products, Services and Solutions

Table 64. Revenue (US$ Million) in Gastroesophageal Reflux Disease Therapeutics Business of Ironwood Pharmaceuticals (2019-2024)

Table 65. Ironwood Pharmaceuticals Recent Developments

Table 66. Key Raw Materials Lists

Table 67. Raw Materials Key Suppliers Lists

Table 68. Gastroesophageal Reflux Disease Therapeutics Downstream Customers

Table 69. Gastroesophageal Reflux Disease Therapeutics Distributors List

Table 70. Research Programs/Design for This Report

Table 71. Key Data Information from Secondary Sources

Table 72. Key Data Information from Primary Sources

Table 73. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Gastroesophageal Reflux Disease Therapeutics Product Picture

Figure 2. Global Gastroesophageal Reflux Disease Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Gastroesophageal Reflux Disease Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 4. Gastroesophageal Reflux Disease Therapeutics Report Years Considered

Figure 5. Global Gastroesophageal Reflux Disease Therapeutics Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Gastroesophageal Reflux Disease Therapeutics Revenue in 2023

Figure 7. Gastroesophageal Reflux Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Antacids Picture

Figure 9. H2 Receptor Blockers Picture

Figure 10. Proton Pump Inhibitors (PPIs) Picture

Figure 11. Pro-kinetic Agents Picture

Figure 12. Others Picture

Figure 13. Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Gastroesophageal Reflux Disease Therapeutics Sales Value Market Share by Type, 2023 & 2030

Figure 15. Product Picture of Hospital Pharmacy

Figure 16. Product Picture of Drug Stores

Figure 17. Product Picture of General Stores

Figure 18. Product Picture of Supermarkets

Figure 19. Global Gastroesophageal Reflux Disease Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 20. Global Gastroesophageal Reflux Disease Therapeutics Sales Value Market Share by Application, 2023 & 2030

Figure 21. North America Gastroesophageal Reflux Disease Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 22. North America Gastroesophageal Reflux Disease Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 23. Europe Gastroesophageal Reflux Disease Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 24. Europe Gastroesophageal Reflux Disease Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 25. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 26. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 27. South America Gastroesophageal Reflux Disease Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 28. South America Gastroesophageal Reflux Disease Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 29. Middle East & Africa Gastroesophageal Reflux Disease Therapeutics Sales Value (2019-2030) & (US$ Million)

Figure 30. Middle East & Africa Gastroesophageal Reflux Disease Therapeutics Sales Value by Country (%), 2023 VS 2030

Figure 31. Key Countries/Regions Gastroesophageal Reflux Disease Therapeutics Sales Value (%), (2019-2030)

Figure 32. United States Gastroesophageal Reflux Disease Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 33. United States Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 34. United States Gastroesophageal Reflux Disease Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 35. Europe Gastroesophageal Reflux Disease Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 36. Europe Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 37. Europe Gastroesophageal Reflux Disease Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 38. China Gastroesophageal Reflux Disease Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 39. China Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 40. China Gastroesophageal Reflux Disease Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 41. Japan Gastroesophageal Reflux Disease Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 42. Japan Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 43. Japan Gastroesophageal Reflux Disease Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 44. South Korea Gastroesophageal Reflux Disease Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 45. South Korea Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 46. South Korea Gastroesophageal Reflux Disease Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 47. Southeast Asia Gastroesophageal Reflux Disease Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 48. Southeast Asia Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 49. Southeast Asia Gastroesophageal Reflux Disease Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 50. India Gastroesophageal Reflux Disease Therapeutics Sales Value, (2019-2030) & (US$ Million)

Figure 51. India Gastroesophageal Reflux Disease Therapeutics Sales Value by Type (%), 2023 VS 2030

Figure 52. India Gastroesophageal Reflux Disease Therapeutics Sales Value by Application (%), 2023 VS 2030

Figure 53. Gastroesophageal Reflux Disease Therapeutics Industrial Chain

Figure 54. Gastroesophageal Reflux Disease Therapeutics Manufacturing Cost Structure

Figure 55. Channels of Distribution (Direct Sales, and Distribution)

Figure 56. Bottom-up and Top-down Approaches for This Report

Figure 57. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions